Quantitation of free light chains in serum and the need for standardization

The analysis of serum free light chains (FLC) is now standard of care in the screening, diagnosis, and monitoring of patients suspected of/having multiple myeloma (MM) or other monoclonal gammopathies (MG). Recently, a new FLC immunoassay has become available from Diazyme. The objectives of our study were to analytically validate the Diazyme assay and to determine clinical interchangeability of two different FLC assays in patients with MG and in a presumed healthy population.

 

Learning Objectives